The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

Gilead Sciences (NASDAQ:GILD) shares fell -11% premarket on Monday after the biopharma company reported disappointing results from a late-stage trial for Trodelvy (sacituzumab govitecan-hziy).

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...

But with its cell therapy unit stalling and antibody-drug conjugate Trodelvy facing challenges, the company’s oncology ambitions were brought back under the spotlight during its third-quarter ...

Trodelvy's FDA approval for bladder cancer was rescinded due to unmet survival endpoints in the TROPICS-04 study. The drug remains approved for certain breast cancer treatments, highlighting its ...

Trodelvy shows effectiveness in treating metastatic triple-negative breast cancer, supported by real-world data. Common side effects include neutropenia, anemia, and fatigue, but are generally ...

HIV and oncology product sales drove growth, with significant gains for Biktarvy and Trodelvy. Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally ...